Biodexa Pharmaceuticals Plc
BDRXNASDAQHealthcare● Active
$3.26
$-0.10(-2.98%)
Market Cap$546888
P/E Ratio—
52W High$66.5
52W Low$2.86
Biodexa Pharmaceuticals Plc (BDRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BDRX · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 27, 2026EPS Actual
-$0.00
Est. -$0.01 · +91.4%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 27, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
BDRX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 11, 2026 | — | — | — | — | — | — |
| ▲ Q1 FY2026 | Mar 27, 2026 | -$0.01 | -$0.00 | +91.4% | — | — | — |
| ▲ Q3 FY2025 | Sep 12, 2025 | -$0.00 | -$0.00 | +93.2% | — | — | — |
| ▼ Q2 FY2025 | Apr 11, 2025 | -$0.01 | -$0.01 | -5.3% | — | $0.00B | — |
| ▼ Q3 FY2024 | Sep 26, 2024 | -$0.22 | -$0.33 | -49.8% | — | $0.00B | — |
| — Q2 FY2024 | Apr 19, 2024 | -$3.54 | -$3.54 | -0.1% | $0.00B | $0.00B | +0.2% |
| — Q3 FY2023 | Sep 15, 2023 | — | -$2773.25 | — | $0.00B | — | — |
| — Q2 FY2023 | Apr 28, 2023 | — | -$36466.51 | — | $0.00B | — | — |
Q3 FY2026
Sep 11, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 27, 2026Beat
EPS Actual
-$0.00
EPS Est.
-$0.01
EPS Surpr.
+91.4%
Revenue
—
Q3 FY2025
Sep 12, 2025Beat
EPS Actual
-$0.00
EPS Est.
-$0.00
EPS Surpr.
+93.2%
Revenue
—
Q2 FY2025
Apr 11, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.01
EPS Surpr.
-5.3%
Revenue
—
Q3 FY2024
Sep 26, 2024Miss
EPS Actual
-$0.33
EPS Est.
-$0.22
EPS Surpr.
-49.8%
Revenue
—
Q2 FY2024
Apr 19, 2024
EPS Actual
-$3.54
EPS Est.
-$3.54
EPS Surpr.
-0.1%
Revenue
$0.00B
Q3 FY2023
Sep 15, 2023
EPS Actual
-$2773.25
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Apr 28, 2023
EPS Actual
-$36466.51
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q2 FY2024 | $-0.00 | $-0.00 | $-0.00 | 1 |
| Q2 FY2019 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2019 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2019 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2019 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 27, 2026 | +91.4% | $3.30 | $3.27 | -0.91% |
| ▲ Q3 FY2025 | Sep 12, 2025 | +93.2% | $29.65 | $30.10 | +1.52% |
| ▼ Q2 FY2025 | Apr 11, 2025 | -5.3% | $78.50 | $88.50 | +12.74% |
| ▼ Q3 FY2024 | Sep 26, 2024 | -49.8% | $364.50 | $369.00 | +1.23% |
| ▲ Q2 FY2024 | Apr 19, 2024 | -0.1% | $1,025.00 | $940.00 | -8.29% |
| — Q3 FY2023 | Sep 15, 2023 | — | $7,687.50 | $7,725.00 | +0.49% |
| — Q2 FY2023 | Apr 28, 2023 | — | $24,180.00 | $22,620.00 | -6.45% |
| — Q3 FY2022 | Sep 14, 2022 | — | $1,400,000.00 | $1,446,002.00 | +3.29% |
Q1 FY2026-0.91%
Report Date
Mar 27, 2026
EPS Beat/Miss
+91.4%
Price Before
$3.30
Price After
$3.27
Q3 FY2025+1.52%
Report Date
Sep 12, 2025
EPS Beat/Miss
+93.2%
Price Before
$29.65
Price After
$30.10
Q2 FY2025+12.74%
Report Date
Apr 11, 2025
EPS Beat/Miss
-5.3%
Price Before
$78.50
Price After
$88.50
Q3 FY2024+1.23%
Report Date
Sep 26, 2024
EPS Beat/Miss
-49.8%
Price Before
$364.50
Price After
$369.00
Q2 FY2024-8.29%
Report Date
Apr 19, 2024
EPS Beat/Miss
-0.1%
Price Before
$1,025.00
Price After
$940.00
Q3 FY2023+0.49%
Report Date
Sep 15, 2023
EPS Beat/Miss
—
Price Before
$7,687.50
Price After
$7,725.00
Q2 FY2023-6.45%
Report Date
Apr 28, 2023
EPS Beat/Miss
—
Price Before
$24,180.00
Price After
$22,620.00
Q3 FY2022+3.29%
Report Date
Sep 14, 2022
EPS Beat/Miss
—
Price Before
$1,400,000.00
Price After
$1,446,002.00
Avg Beat Reaction-2.56%
Avg Miss Reaction+6.99%
Beat Rate3 / 8 quarters
Largest Move+12.74% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BDRX ends December
Biodexa Pharmaceuticals Plc (BDRX) most recently reported earnings on March 27, 2026 for Q1 FY2026, posting EPS of $-0.00 — beating the analyst consensus of $-0.01 by +91.4%. BDRX has beaten EPS estimates for 2 consecutive quarters. The next BDRX earnings date is expected around September 1, 2026.
Each quarter, investors track BDRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BDRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BDRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BDRX earnings · 5 questionsBiodexa Pharmaceuticals Plc's next earnings report is expected around September 1, 2026. BDRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BDRX historically reports after market close (AMC).
BDRX earnings datewhen is BDRX earningsBDRX next earnings datewhen does BDRX report earningsBDRX earnings calendar
▸ Source: FMP · Biodexa Pharmaceuticals Plc SEC filings · US GAAP · Biodexa Pharmaceuticals Plc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026